Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis: A Retrospective Analysis of 527 Patients From the Polish Adult Leukemia Group Registry.

Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis: A Retrospective Analysis of 527 Patients From the Polish Adult Leukemia Group Registry. Clin Lymphoma Myeloma Leuk. 2018 May 09;: Authors: Gora-Tybor J, Sacha T, Wącław J, Niesiobędzka-Krężel J, Grzybowska-Izydorczyk O, Mędraś E, Dereń-Wagemann I, Patkowska E, Seferyńska I, Lewandowski K, Wache A, Blajer-Olszewska B, Wątek M, Kotwica-Mojzych K, Wasilewska E, Warzocha K, Jamroziak K PMID: 29778693 [PubMed - as supplied by publisher]
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Related Links:

Publication date: Available online 9 November 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Aleeza Abbasi, Catherine Chung, Basem M. William
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 9 November 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Prajwal Dhakal, Elizabeth Lyden, Andrea Lee, Joel Michalski, Zaid S. Al-Kadhimi, Lori J. Maness, Krishna Gundabolu, Vijaya Raj BhattAbstractBackgroundThe role of obesity in prognosis of acute myeloid leukemia(AML) is debatable. Our retrospective study aimed to determine the effect of obesity on overall survival(OS) in AML.MethodsAML patients diagnosed at University of Nebraska Medical Center were divided into 3-groups based on body mass index (BMI): normal(18.5-25kg/m2) or underweight(
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 9 November 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Megan Melody, Andrew Kuykendall, David Sallman, Najla Al Ali, Ling Zhang, Chetasi Talati, Eric Padron, Kendra Sweet, Martine Extermann, Alan List, Jeffrey Lancet, Rami KomrokjiAbstractAML in elderly patients (pts) is associated with poor outcomes and often arises from antecedent hematological disorders (AHD), classified as secondary AML (sAML). In order to validate the use of somatic mutations to determine AML ontogeny in the elderly population, we identified 178 elderly (>70yo) AML pts with NexGen Sequencing data....
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 21 October 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Giulia Gabrielli, Alessandro Broccoli, Cinzia Pellegrini, Lisa Argnani, Michele Cavo, Pier Luigi Zinzani
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionsThe comprehensive analysis of clinical characteristics, immunophenotypic profiles and cytogenetic features can be helpful in differential diagnosis, especially for patients without an available non-bone marrow biopsy specimen. Universal prognostic factors may help with the early detection of high-risk patients and with stratification in risk-adapted therapy.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 7 November 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Kaoru Morita, Masahiro Ashizawa, Yumiko Toda, Takashi Ikeda, Shin-ichiro Kawaguchi, Shoko Ito, Shin-ichi Ochi, Takashi Nagayama, Kiyomi Mashima, Kento Umino, Daisuke Minakata, Hirofumi Nakano, Ryoko Yamasaki, Chihiro Yamamoto, Kaoru Hatano, Shin-ichiro Fujiwara, Kazuya Sato, Iekuni Oh, Ken Ohmine, Kazuo MuroiAbstractAbout 40% of patients with diffuse large B cell lymphoma (DLBCL) relapse after or are refractory to standard chemotherapy with rituximab plus cyclophosphamide, hydroxydaunorubicin, vincristine, and prednis...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionsIn summary, CyBorD showed a ≥VGPR rate of 53% with 26.5% achieving CR, which is similar to that seen in previous studies. In addition, MRD negativity assessed by MPF in patients with CR resulted in no difference on survival outcomes.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 6 November 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Benjamin K. Tomlinson, Molly M. Gallogly, Donna M. Kane, Leland Metheny, Hillard M. Lazarus, Basem M. William, Michael D. Craig, Mark J. Levis, Brenda W. CooperAbstract:BackgroundMidostaurin, a multikinase inhibitor, is approved for treatment of FLT3 mutant acute myeloid leukemia (AML). A phase I study established that midostaurin 75 mg orally twice daily for 14 days with standard dose azacitidine was safe and tolerable in elderly AML. Herein, we report the phase II expansion cohort of previously untreated elderly or ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
AML in elderly patients (pts) is associated with poor outcomes and often arises from antecedent hematological disorders (AHD), classified as secondary AML (sAML). In order to validate the use of somatic mutations to determine AML ontogeny in the elderly population, we identified 178 elderly (>70yo) AML pts with NexGen Sequencing data. Pts were divided clinically into pAML or sAML based on prior history of AHD. Pts were then reclassified into 4 groups based on somatic mutations and cytogenetics as suggested by Lindsley et al: group 1 (pAML) with CBF rearrangements, 11q23/MLL, and NPM1 mutation (MT); group 2 (sAML) with S...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Lymphocytic variant of Hypereosinophilic syndrome (L-HES) is a rare condition characterized by esosinophilia associated with the presence of clonal T-cells.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
More News: Leukemia | Lymphoma | Myeloma | Poland Health